10-K: Protagenic Therapeutics Reports 2024 Financial Results and Provides Business Update

Protagenic Therapeutics, Inc. files its annual report on Form 10-K, detailing its financial results for the year ended December 31, 2024, and providing an update on its clinical development programs and corporate strategy.

Summary

• Protagenic Therapeutics, Inc. reported a loss from operations of $5,700,950 for the year ended December 31, 2024, compared to $4,526,974 for the year ended December 31, 2023.
• The increase in the loss is primarily due to an increase in research and development expenses and general and administrative expenses.
• The Company's cash resources are expected to be sufficient to fund operations until approximately the end of the third quarter of 2025.
• The Company is in the process of refiling its IND application for PT00114 addressing the questions raised by regulators.
• The Company anticipates commencing the multiple dose portion of the Phase I study for PT00114 in Q2 2025 and expects to announce the results in the same quarter.
• The Company anticipates initiating the Phase IIa study for PT00114 in Q3 2025.
• The Company is focused on confirming the efficacy of PT00114 and progressing towards human clinical trials and commercialization.
• The Company is working to regain compliance with Nasdaq listing requirements, with a deadline of April 28, 2025, to demonstrate compliance.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical development, the company faces significant financial challenges, including operating losses, limited cash resources, and the need for additional funding. The potential delisting from Nasdaq adds further uncertainty.

Positives

• The Company is actively progressing its lead product candidate, PT00114, through clinical trials.
• The Company has a clear plan of operations with anticipated development milestones.
• The Company has a shelf registration statement allowing it to issue up to $100 million of securities.
• The Company has an At Market Issuance Agreement to sell shares of common stock.
• The Company has a strong scientific advisory team and collaborations with leading researchers.
• The Company is actively working to address Nasdaq listing deficiencies.

Negatives

• The Company has incurred significant operating losses and has an accumulated deficit of $36,303,216 as of December 31, 2024.
• The Company expects to continue to incur substantial operating losses over the next several years.
• The Company's cash resources are only expected to be sufficient to fund operations until approximately the end of the third quarter of 2025.
• The Company has identified material weaknesses in its internal control over financial reporting.
• The Company is not in compliance with Nasdaq's minimum bid price requirement and faces potential delisting.

Risks

• The Company's financial statements have been prepared on a going concern basis, and there is substantial doubt about its ability to continue as a going concern.
• The Company needs to obtain financing in order to continue its operations, and additional financing may not be available on acceptable terms, or at all.
• The Company has a limited operating history and a high risk of never being profitable.
• The market price of the Company's common stock may be volatile, and investors could lose all or part of their investment.
• The Company may not be able to maintain its exclusive worldwide license to use and develop PT00114.
• The Company may not be able to obtain and maintain the third party relationships that are necessary to develop, commercialize and manufacture some or all of its product candidates.
• The Company may not be able to gain market acceptance of its product candidates, which would prevent it from becoming profitable.
• The Company may not be able to manufacture its product candidates in clinical or commercial quantities, which would prevent it from commercializing its product candidates.
• The Company may encounter difficulties in managing its growth, which could adversely affect its operations.
• The Company's business and operations are vulnerable to computer system failures, cyber-attacks or deficiencies in its cyber-security, which could increase its expenses, divert the attention of its management and key personnel away from its business operations and adversely affect its results of operations.

Future Outlook

The Company anticipates commencing the multiple dose portion of the Phase I study for PT00114 in Q2 2025 and expects to announce the results in the same quarter. The Company anticipates initiating the Phase IIa study for PT00114 in Q3 2025. The Company expects its cash resources to be sufficient to fund operations until approximately the end of the third quarter of 2025.

Management Comments

• Management concluded that, during the year-ended December 31, 2024, our internal controls and procedures were not effective to detect the inappropriate application of U.S. GAAP.

Industry Context

The report acknowledges the competitive landscape of the pharmaceutical and biotechnology industries, highlighting the need for Protagenic to compete with companies that have greater resources and experience. It also notes the challenges in developing effective treatments for neuropsychiatric disorders and the potential for competitors to develop products that could render Protagenic's product candidates obsolete.

Comparison to Industry Standards

• The report mentions several drugs that have launched in recent years to validate the market for branded agents in the treatment resistant depression field, in spite of their marginal improvements in safety or efficacy.
• The report mentions several drugs that can be used to treat AUD, which can lead to reduced heavy drinking and increased days of abstinence.
• The report mentions Vivitrol, an extended-release injectable naltrexone that allows for once monthly dosing that was approved in 2006. Vivitrol is priced at $~1,738/month and 2023 worldwide sales have grown to $400.4 million.

Related Party Transactions

• The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen.
• The Company engaged Agenus Inc., a related party, to perform research and development services.
• The Company engaged CTC North, GmbH (CTC) to perform research and development services.

Stakeholder Impact

• Shareholders may experience dilution of their ownership interests due to future issuance of additional shares of common stock.
• The Company's ability to continue as a going concern is dependent on obtaining additional financing, which may impact stakeholders.
• Employees may be affected by potential curtailment of development efforts and planned operations if additional funding is not secured.

Next Steps

• The Company is in the process of refiling its IND application for PT00114 addressing the questions raised by regulators.
• The Company anticipates commencing the multiple dose portion of the Phase I study for PT00114 in Q2 2025.
• The Company anticipates initiating the Phase IIa study for PT00114 in Q3 2025.
• The Company has until April 28, 2025 to demonstrate compliance with Nasdaq listing requirements.

Key Dates

Keywords

PT00114, clinical trials, neuropsychiatric disorders, mood disorders, biopharmaceutical, financial results, Protagenic Therapeutics, TCAP, Nasdaq, operating losses